Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Depreciation (2016)

Agios Pharmaceuticals (AGIO) has disclosed Accumulated Depreciation for 5 consecutive years, with $13.4 million as the latest value for Q4 2016.

  • For Q4 2016, Accumulated Depreciation rose 74.48% year-over-year to $13.4 million; the TTM value through Dec 2016 reached $13.4 million, up 74.48%, while the annual FY2016 figure was $13.4 million, 74.48% up from the prior year.
  • Accumulated Depreciation hit $13.4 million in Q4 2016 for Agios Pharmaceuticals, up from $7.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $13.4 million in Q4 2016 and bottomed at $2.8 million in Q4 2012.
  • Average Accumulated Depreciation over 5 years is $6.7 million, with a median of $5.6 million recorded in 2014.
  • Year-over-year, Accumulated Depreciation soared 32.62% in 2014 and then surged 74.48% in 2016.
  • Agios Pharmaceuticals' Accumulated Depreciation stood at $2.8 million in 2012, then soared by 52.34% to $4.2 million in 2013, then skyrocketed by 32.62% to $5.6 million in 2014, then skyrocketed by 37.89% to $7.7 million in 2015, then soared by 74.48% to $13.4 million in 2016.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $13.4 million, $7.7 million, and $5.6 million for Q4 2016, Q4 2015, and Q4 2014 respectively.